$1.82
4.00% today
Nasdaq, Dec 04, 09:42 pm CET
ISIN
US45674E1091
Symbol
INAB

IN8bio Inc Stock price

$1.75
-0.13 6.91% 1M
-1.96 52.84% 6M
-5.97 77.32% YTD
-7.83 81.73% 1Y
-71.45 97.61% 3Y
-298.25 99.42% 5Y
-298.25 99.42% 10Y
-298.25 99.42% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
-0.03 1.69%
ISIN
US45674E1091
Symbol
INAB
Industry

Key metrics

Basic
Market capitalization
$8.1m
Enterprise Value
$-2.2m
Net debt
positive
Cash
$10.7m
Shares outstanding
4.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.1
P/B
0.6
Financial Health
Equity Ratio
69.1%
Return on Equity
-210.2%
ROCE
-139.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-19.8m | $-15.3m
EBIT
$-21.1m | $-19.8m
Net Income
$-20.7m | $-23.6m
Free Cash Flow
$-14.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
32.7% | 44.9%
EBIT
33.7% | 33.0%
Net Income
35.2% | 22.5%
Free Cash Flow
41.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.6
FCF per Share
$-3.2
Short interest
0.9%
Employees
18
Rev per Employee
$0.0
Show more

Is IN8bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

IN8bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a IN8bio Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a IN8bio Inc forecast:

Buy
90%
Hold
10%

Financial data from IN8bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.90 9.90
29% 29%
-
- Research and Development Expense 11 11
38% 38%
-
-20 -20
33% 33%
-
- Depreciation and Amortization 1.29 1.29
46% 46%
-
EBIT (Operating Income) EBIT -21 -21
34% 34%
-
Net Profit -21 -21
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about IN8bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IN8bio Inc Stock News

Neutral
GlobeNewsWire
28 days ago
Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine release, highlighting its potential to achieve deep B cell depletion with an improved safety profile Expanded Phase 1 INB-100 trial to The James Comprehensive Cancer Center at The Ohio State Univer...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that The Ohio State University has been added as a new clinical site in the ongoing Phase 1 trial of the Company's INB-100, a donor-derived allogeneic gamma-delta T cell therapy ...
Neutral
GlobeNewsWire
about one month ago
INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with minimal adverse cytokine release, highlighting a targeted approach that potentially allows for safer deep B cell depletion. INB-619 is the first pan-gamma delta (γδ) T cell engager designed to significantly expand multiple γδ T cell subsets for efficient...
More IN8bio Inc News

Company Profile

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

Head office United States
CEO William Ho
Employees 18
Founded 2016
Website www.in8bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today